RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
In this phase II trial the investigators plan to incorporate two targeted agents, bevacizumab
and everolimus, into the first-line multimodality therapy of glioblastoma. In the first
portion of the treatment, bevacizumab will be added to standard concurrent radiation therapy
plus temozolomide. After completing radiation therapy, patients will continue treatment with
the combination of bevacizumab and everolimus.